Article Information
History
- July 2, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Bharti Wadhwa1,*,
- Vikas Malhotra2,
- Sukhyanti Kerai1,
- Farah Husain1,
- Nalini Bala Pandey1,
- Kirti N Saxena1,
- Vinay Singh1,
- Tom M Quinn3,4,*,
- Feng Li3,
- Erin Gaughan3,4,
- Manu Shankar-Hari3,
- Bethany Mills3,
- Jean Antonelli3,
- Annya Bruce3,
- Keith Finlayson3,
- Anne Moore3,
- Kevin Dhaliwal3,4,* and
- Christopher Edwards5,*
- 1Department of Anaesthesia, Maulana Azad Medical College, New Delhi, India
- 2Department of ENT & Head and Neck Surgery, Maulana Azad Medical College & Associated Hospitals, New Delhi, India
- 3Centre for Inflammation Research, The Queen’s Medical Research Institute, BioQuarter, The University of Edinburgh, Edinburgh, EH16 4TJ, UK
- 4Royal Infirmary of Edinburgh, BioQuarter, Little France, Edinburgh, EH16 4SA, UK
- 5Imperial College, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK
- ↵*Corresponding authors; email: tquinn{at}ed.ac.uk
Posted July 02, 2022.
Phase 2 randomised placebo-controlled trial of spironolactone and dexamethasone versus dexamethasone in COVID-19 hospitalised patients in Delhi
